The fully synthetic short peptides, known as Bicycles, could become effective agents for molecular imaging to help choose the most appropriate targeted therapy and to monitor patients' responses to treatment, according to the company. The research was conducted in collaboration with the German Cancer Research Center (DKFZ).

The firm is developing Bicycles for the treatment of cancer, as well as in collaboration with others for therapeutic areas that could include respiratory, cardiovascular, hematology, and infectious diseases.